How has been the historical performance of Dr Lal Pathlabs?

Jul 31 2025 10:42 PM IST
share
Share Via
Dr Lal Pathlabs has shown consistent growth from March 2019 to March 2025, with net sales increasing from INR 1,203.40 crore to INR 2,461.40 crore and profit after tax rising from INR 200.50 crore to INR 492.20 crore. The company's earnings per share also grew significantly, reaching INR 58.27 in March 2025.
Answer:
The historical performance of Dr Lal Pathlabs shows a consistent growth trajectory in net sales and profits over the years leading up to March 2025. Breakdown: Dr Lal Pathlabs has demonstrated significant growth in net sales, increasing from INR 1,203.40 crore in March 2019 to INR 2,461.40 crore in March 2025. This upward trend is reflected in total operating income, which rose from INR 1,203.40 crore in March 2019 to INR 2,461.40 crore in March 2025. The company has also seen a steady increase in operating profit, which reached INR 788.90 crore in March 2025, up from INR 339.60 crore in March 2019. Profit before tax has similarly improved, climbing to INR 624.70 crore in March 2025 from INR 300.60 crore in March 2019. Consequently, profit after tax surged to INR 492.20 crore in March 2025, compared to INR 200.50 crore in March 2019. The earnings per share (EPS) also reflect this growth, increasing to INR 58.27 in March 2025 from INR 23.91 in March 2019. On the balance sheet, total assets rose from INR 1,351.46 crore in March 2020 to INR 2,630.17 crore in March 2025, while total liabilities increased from INR 1,351.46 crore to INR 2,630.17 crore in the same period. Cash flow from operating activities improved to INR 568.00 crore in March 2025 from INR 283.00 crore in March 2020, although the net cash flow showed a decrease to -68.00 crore in March 2025 from 67.00 crore in March 2020. Overall, Dr Lal Pathlabs has shown a robust performance with increasing revenues, profits, and asset growth over the years.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Dr Lal Pathlabs Ltd is Rated Sell
Mar 28 2026 10:10 AM IST
share
Share Via
Dr Lal Pathlabs Ltd is Rated Sell
Mar 17 2026 10:10 AM IST
share
Share Via
Dr Lal Pathlabs Ltd is Rated Sell
Mar 06 2026 10:10 AM IST
share
Share Via
Why is Dr Lal Pathlabs Ltd falling/rising?
Mar 06 2026 01:18 AM IST
share
Share Via
Dr Lal Pathlabs Ltd is Rated Sell
Feb 23 2026 10:10 AM IST
share
Share Via